BR0214075A - Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação - Google Patents

Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação

Info

Publication number
BR0214075A
BR0214075A BR0214075-6A BR0214075A BR0214075A BR 0214075 A BR0214075 A BR 0214075A BR 0214075 A BR0214075 A BR 0214075A BR 0214075 A BR0214075 A BR 0214075A
Authority
BR
Brazil
Prior art keywords
unit dosage
prostaglandin analog
constipation
treat constipation
analog
Prior art date
Application number
BR0214075-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ueno
Myra L Patchen
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0214075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR0214075A publication Critical patent/BR0214075A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
BR0214075-6A 2001-11-14 2002-11-14 Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação BR0214075A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
PCT/JP2002/011862 WO2003041716A1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Publications (1)

Publication Number Publication Date
BR0214075A true BR0214075A (pt) 2004-09-28

Family

ID=23293447

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214075-6A BR0214075A (pt) 2001-11-14 2002-11-14 Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação

Country Status (14)

Country Link
US (3) US8097653B2 (enExample)
EP (2) EP1443938B1 (enExample)
JP (2) JP4852229B2 (enExample)
AR (3) AR037524A1 (enExample)
AT (1) ATE522218T1 (enExample)
BR (1) BR0214075A (enExample)
CA (1) CA2464420C (enExample)
CY (1) CY1115856T1 (enExample)
DK (2) DK1443938T3 (enExample)
ES (2) ES2368729T3 (enExample)
LU (1) LU92826I2 (enExample)
PT (2) PT2298314E (enExample)
TW (1) TWI331920B (enExample)
WO (1) WO2003041716A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
AU2003292556B2 (en) * 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
CA2637275C (en) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
RU2420291C3 (ru) * 2006-01-24 2020-07-21 Р-Тек Уено, Лтд. Состав в мягкой желатиновой капсуле
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
US6242485B1 (en) * 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
EP0978284B1 (en) 1997-11-28 2008-07-23 Sucampo AG Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
DE60039727D1 (de) * 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
JP4183943B2 (ja) 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
AU2003292556B2 (en) 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
JP4852229B2 (ja) 2012-01-11
JP2011201905A (ja) 2011-10-13
DK1443938T3 (da) 2011-09-26
TW200300091A (en) 2003-05-16
US20130143958A1 (en) 2013-06-06
EP1443938A1 (en) 2004-08-11
AR037524A1 (es) 2004-11-17
JP2005513014A (ja) 2005-05-12
WO2003041716A1 (en) 2003-05-22
LU92826I2 (fr) 2015-11-24
PT1443938E (pt) 2011-09-27
ATE522218T1 (de) 2011-09-15
US8097653B2 (en) 2012-01-17
US20120088824A1 (en) 2012-04-12
CY1115856T1 (el) 2017-01-25
ES2524369T3 (es) 2014-12-05
EP1443938B1 (en) 2011-08-31
EP2298314B1 (en) 2014-09-03
CA2464420A1 (en) 2003-05-22
HK1155649A1 (en) 2012-05-25
US20030119898A1 (en) 2003-06-26
DK2298314T3 (en) 2014-12-01
CA2464420C (en) 2011-12-13
US8389542B2 (en) 2013-03-05
PT2298314E (pt) 2014-12-03
AR117404A2 (es) 2021-08-04
AR098997A2 (es) 2016-06-22
TWI331920B (en) 2010-10-21
EP2298314A1 (en) 2011-03-23
ES2368729T3 (es) 2011-11-21

Similar Documents

Publication Publication Date Title
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
CY1115856T1 (el) Μοναδα δοσολογιας περιεχουσα αναλογο προσταγλανδινης για την αγωγη της δυσκοιλιοτητας
BR0110420A (pt) Agonistas muscarìnicos
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
ATE429904T1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
CA2503810A1 (en) Therapeutic agent for fibromyalgia
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
EP1806135A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
BR0109753A (pt) Combinação farmacêutica, formulação farmacêutica, conjunto de partes, método para tratamento profilático ou terapêutico de um paciente que sofre de, ou é suscetìvel a, aterosclerose, e, usos de uma formulação, de uma combinação, ou de um conjunto de partes
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
MX9805441A (es) Compuestos terapeuticos.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]